HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vitamin D And COVID-19 Studies: Prevention Benefits Suggested By Chicago Research

Executive Summary

A study with nearly 500 patients with vitamin D levels tested within a year before receiving COVID-19 tests found subjects deficient in the nutrient had 1.77 greater chance of testing positive. Researchers say RCTs are needed to determine if broad population interventions are necessary.

You may also be interested in...



Canadian Study Doubts Vitamin D Impact Against COVID-19 As Others Show Protection Correlation

McGill University researchers say multiple analyses of genetic variants study showed no association between genetically predicted vitamin D level and COVID-19 susceptibility, hospitalization or severe disease. CRN’s Vitamin D & Me! campaign reaches 5.6m consumers.

French Experts Call For Mass Vitamin D Supplementation To Fight COVID-19

With around half the French population vitamin D deficient, a group of medical experts say mass supplementation is a low cost and low risk intervention which could save lives and curb the spread of COVID-19.

Separation Key To Posting Studies Linking Dietary Ingredients To Preventing Or Treating Disease

DSHEA’s Scientific Literature Exemption is attracting attention for offering online studies showing nutrients’ benefits on diseases including COVID-19, though the method isn’t free of risks, suggests CRN executive Megan Olsen.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS150481

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel